Loading clinical trials...
Loading clinical trials...
Defining the Role of ctDNA Monitoring in a Risk Stratified Clinical Trial for Posttransplant Lymphoproliferative Disorder (PTLD)
Conditions
Interventions
Rituximab
Etoposide
+5 more
Locations
2
United States
Stanford Medical Center
Stanford, California, United States
Columbia University Irving Medical Center
New York, New York, United States
Start Date
April 14, 2025
Primary Completion Date
April 14, 2027
Completion Date
April 14, 2028
Last Updated
May 2, 2025
NCT07545603
NCT07137494
NCT05969860
NCT05475925
NCT07218341
NCT03618550
Lead Sponsor
Jennifer Amengual
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions